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Abstract
Background and Objectives—Alcohol abuse complicates treatment of HIV disease and is
linked to poor outcomes. Alcohol pharmacotherapies, including disulfiram (DIS), are infrequently
utilized in co-occurring HIV and alcohol use disorders possibly related to concerns about drug
interactions between antiretroviral (ARV) medications and DIS.
Method—This pharmacokinetics study (n=40) examined the effect of DIS on efavirenz (EFV),
ritonavir (RTV), or atazanavir (ATV) and the effect of these ARV medications on DIS metabolism
and aldehyde dehydrogenase (ALDH) activity which mediates the DIS-alcohol reaction.
Results—EFV administration was associated with decreased S-Methyl-N-N-
diethylthiocarbamate (DIS carbamate), a metabolite of DIS (p=0.001) and a precursor to the
metabolite responsible for ALDH inhibition, S-methyl-N,N-diethylthiolcarbamate sulfoxide
(DETC-MeSO). EFV was associated with increased DIS inhibition of ALDH activity relative to
DIS alone administration possibly as a result of EFV-associated induction of CYP 3A4 which
metabolizes the carbamate to DETC-MeSO (which inhibits ALDH). Conversely, ATV co-
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administration reduced the effect of DIS on ALDH activity possibly as a result of ATV inhibition
of CYP 3A4. DIS administration had no significant effect on any ARV studied.
Discussion/Conclusions—ATV may render DIS ineffective in treatment of alcoholism.
Future Directions—DIS is infrequently utilized in HIV-infected individuals due to concerns
about adverse interactions and side effects. Findings from this study indicate that, with ongoing
clinical monitoring, DIS should be reconsidered given its potential efficacy for alcohol and
potentially, cocaine use disorders, that may occur in this population.
Keywords
disulfiram; alcohol abuse; efavirenz; ritonavir; atazanavir; drug interactions; aldehyde
dehydrogenase
Introduction
Disulfiram (DIS) (Antabuse®) is a U.S. Food and Drug Administration (FDA) approved
pharmacotherapy for the treatment of alcohol dependence. DIS is a relatively irreversible
inhibitor of sulfhydryl-containing enzymes (1). The target enzyme for the pharmacologic
effect of DIS in the treatment of alcohol addiction is aldehyde dehydrogenase (ALDH). This
enzyme converts acetaldehyde to acetate in alcohol metabolism. The increased concentration
of acetaldehyde after alcohol ingestion in the presence of DIS is responsible for the DIS-
alcohol reaction. This reaction is characterized by flushing, weakness, nausea, tachycardia,
and in some instances, hypotension (2). In addition to its use as a deterrent to alcohol
consumption, DIS has shown promise as a potential pharmacotherapy for cocaine abuse (3).
Clinical trials have shown decreases in cocaine and alcohol use with DIS 250 mg daily
administration (4) while human laboratory studies have shown significant decreases in
cocaine “high” and “rush” when cocaine was administered by the intravenous route in a
double-blind, randomized study in which either DIS 0, 62.5 mg or 250 mg daily was
administered chronically (5).
Substance abuse is common in those with HIV infection (6, 7) and the availability of
addiction pharmacotherapy for this population is important. For example, the clinical benefit
of opioid therapies including methadone and buprenorphine to treat opioid dependence,
often in injection drug users who have contracted HIV infection through high risk injection
practices, has been clearly demonstrated (8). However, medications to treat alcoholism are
used infrequently although alcohol abuse is a significant problem complicating the treatment
of HIV disease and has been linked to poor HIV outcomes (9–11). The potential of DIS for
adverse drug-drug interactions with antiretroviral medications (ARV) is a significant
concern that could be a factor in diminishing consideration of use of this medication in those
with alcoholism and HIV disease.
DIS must be bioactivated through a series of intermediates, ultimately forming S-methyl-
N,N-diethylthiolcarbamate sulfoxide (DETC-MeSO), the metabolite proposed to be
responsible for the in vivo inhibition of ALDH (12, 13). Bioactivation of DIS to the active
metabolite associated with the DIS-alcohol reaction, DETC-MeSO, occurs principally via
cytochrome P450 (CYP) 3A4/5, with contributions by CYP1A2, -2A6 and -2D6 (14, 15).
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Inhibition by DIS of CYP450 enzymes, mainly 2E1 (16, 17) and 1A2 (18, 19), and
demethylation function has been reported (20). Therefore, this study investigated any
potential effect on CYP450 enzymes by DIS that might alter the metabolism of ARV,
specifically efavirenz (EFV), ritonavir (RTV), and atazanavir (ATV) since these ARV are
substrates of CYP3A4/5 and -2B6. Also important was the determination of whether DIS
would be efficacious as a treatment for alcohol dependence when co-administered with
ARV that could potentially alter DIS metabolism. For example, EFV has been reported to
induce CYP3A4 activity (21, 22) while RTV is a potent inhibitor of CYP3A4 (23).
Therefore, the effects of ARV administration on DIS metabolism were also examined.
Methods
Forty individuals participated in this project composed of four separate pharmacokinetics
study components with 10 participants enrolled in each component which included
determination of pharmacokinetics for 1. DIS alone, 2. DIS/EFV, 3. DIS/RTV, and 4. DIS/
ATV. The study was reviewed and approved by the Institutional Review Board at the
University of California San Francisco (UCSF) and is registered at ClinicalTrials.gov
(NCT00878306). Participants were healthy subjects with health status determined by
medical history and physical examination, psychological testing (Mini-International
Neuropsychiatric Interview (24), laboratory testing, and cardiogram which were within
normal ranges at baseline (Table 1). Participants were taking no other medications that
might impact CYP 450 function. All participants were confirmed to have no evidence of
HIV infection (by HIV antibody and HIV viral load tests). Participants were tested for
ALDH activity which is a marker of DIS ability to induce a DIS-alcohol reaction (i.e.:
whether DIS would be expected to be effective as a deterrent to alcohol use) and underwent
pharmacokinetics studies in which a within-subjects analysis was used to determine the
effect of ARV combined with DIS on ALDH activity. A between-subjects analysis was used
to examine the effect of ARV on the DIS metabolite, S-Methyl-N-N-diethylthiocarbamate
(DIS carbamate), and the effect of DIS on ARV.
Each study component was conducted independently and was open-label to increase the
safety of the study participants. Participants in the DIS alone group received DIS 62.5 mg
daily for 4 days followed by a pharmacokinetics study over 10 hours. Participants were then
placed on DIS 250 mg daily and received this medication for 4 days followed by another
pharmacokinetics study. Blood samples for DIS alone pharmacokinetics studies were
collected at 0, 0.5, 1, 2, 4, 6, 8, and 10 hours. Volunteers who participated in the DIS/ARV
studies were assigned to receive clinical doses of either EFV 600 mg daily for 10 days or
RTV 200 mg daily for 8 days or ATV 400 mg daily for 8 days. Upon completion of the
dosing period for the ARV, either a 12 hour (RTV) or 24 hour (ATV or EFV)
pharmacokinetics study was undertaken in which ARV samples were collected at 0, 0.5, 1,
1.5, 2, 4, 6, 8, 12 and 24 hours (the latter sample for EFV and ATV studies). Once the ARV
pharmacokinetics study was completed, participants began a 4 day course of DIS 62.5 mg
daily with continued ARV medication followed by a second pharmacokinetics study in
which both DIS and the ARV of interest were sampled as previously described. A four day
washout of DIS with continued ARV administration was followed by a dosing period of 4
days with DIS 250 mg daily. All medication ingestion was observed by study staff with the
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exception of EFV which is generally given in the evening when used for HIV treatment.
Four days prior to the pharmacokinetics studies, EFV dosing was changed to mornings and
all dosing was observed. The final pharmacokinetics study of ARV and DIS 250 mg was
undertaken as described above. Blood samples for ALDH were collected at baseline (prior
to receiving any study medications) and following completion of study medication observed
dosing (e.g.: Day 4 following DIS 62.5 mg daily and Day 4 following DIS 250 mg daily
dosing for DIS alone and similarly following DIS administration in combination with ARV
medications). Each ALDH sample was collected prior to DIS or DIS + ARV dosing at the
time of the pharmacokinetics study. Adverse symptoms were recorded for all participants
using an Adverse Symptoms Checklist (25) that queried for a wide range of adverse
experiences including changes in energy, gastrointestinal symptoms, central nervous system
effects, genitourinary symptoms, and other somatic complaints scored for severity on an
ordinal scale (0–3, with 0=not present, 1=mild, 2=moderate, and 3=severe, maximum
possible score=87). These ratings were administered at baseline, following DIS
administration, following ARV administration, and following administration of ARV and
DIS concomitantly. Upon completion of study procedures, participants received a final




All blood samples were collected in heparinized 6 ml vacutainer tubes. For drug
concentration determination, plasma was separated by centrifugation and stored at −70°C
until shipment. Plasma samples were shipped on dry ice to the University at Buffalo
Translational Pharmacology Research Core and kept at −70°C until assay. Samples were
thawed prior to assays which were conducted as described below. Blood samples for ALDH
determination were collected in heparinized vacutainer tubes and shipped overnight on a
cold pack to the flow cytometery laboratory at Roswell Park Cancer Institute for analysis.
The blood samples were processed for mononuclear cells using histopaque.
ALDH assay
ALDH activity in peripheral blood mononuclear cells was measured using ALDEFLUOR™
Kits. These kits are routinely used to identify stem and progenitor cells expressing high
levels of ALDH (26). Total and control ALDH measurements were performed in triplicate.
Cytofluorometric analysis was performed using a FACSCanto II (BD BioSciences, San Jose,
CA) flow cytometer equipped with 408, 488, and 640 nm lasers. Monocytes were gated and
the net ALDH activity determined by subtracting control from total activity.
S-Methyl-N-N-diethylthiocarbamate (DIS carbamate) and Antiretroviral Assays
DIS carbamate concentrations were determined using ultra performance liquid
chromatography coupled to electrospray tandem mass spectrometry (27). S-Methyl-N-N-
diethylthiocarbamate reference standard (lot number ELZ-125-3, 98% purity) was used to
prepare calibration standards and quality controls and was supplied by Toronto Research
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Chemicals. Ritonavir, atazanavir and efavirenz were quantified using previously published
simultaneous high-performance liquid chromatography (HPLC) assays (28, 29).
Pharmacokinetics and Statistical Analysis
Plasma DIS metabolite and ARV pharmacokinetics were evaluated for each subject.
Standard non-compartmental methods were used to estimate pharmacokinetic parameters
including area under the concentration-time curve (AUCtau,), maximum plasma
concentration (Cmax), time of Cmax(Tmax), elimination half life (T1/2) and oral clearance
(CLss/F), where F is the oral bioavailability. Tmax was estimated by inspection of the raw
data (Phoenix 64, WinNonlin 6.3)
The Kruskal-Wallis test was used to determine the significance of the differences in ARV
pharmacokinetic parameters (e.g.: AUC, Cmax, Cmin) in the absence or presence of DIS 62.5
and DIS 250 mg/d. Determination of differences in effects of ARV on DIS intermediary
metabolite, DIS carbamate, pharmacokinetics parameters were also examined by Kruskal-
Wallis test. ALDH activity was analyzed using a within-subjects approach by paired t-test
with comparison of baseline ALDH and ALDH activity following DIS or DIS/ARV
administration. All differences were considered statistically significant if the p value was ≤




There were no significant differences in age (range 34–45 years), weight (75–87 kg), gender
(samples ranged from 30–60% women), or cigarette use between any of the groups (0–0.1
packs per day) (Table 1). All samples were comprised of healthy subjects and no diagnoses
of medical, mental, or substance use disorders were identified on completion of screening
procedures. Laboratory indices of hepatic function (alanine aminotransferase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase, and total protein) remained within
normal ranges throughout the study period including baseline values, following ARV
administration, DIS administration and combined ARV and DIS administration (Table 1).
Total bilirubin was significantly increased following ATV administration alone and in
combination with DIS. Cardiograms were obtained at baseline and following DIS
administration, ARV administration or combined administration of ARV and DIS. There
was no evidence for clinically significant changes in QT interval under any study condition
(Table1). Administration of DIS, ARV, or DIS concurrently with any of the ARV produced
no significant changes in adverse symptoms from those reported at baseline.
Pharmacokinetic results
Effect of DIS on ARV
Table 2 A–C shows pharmacokinetic parameters for each of the ARV alone or concurrent
with either dose of DIS for 4 days. Neither dose of DIS had a significant effect on any of the
pharmacokinetic parameters examined including total exposure to ARV over time (AUCtau),
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clearance, maximum plasma concentration (Cmax), time to maximum plasma concentration
(Tmax), and elimination half-life.
Effect of ARV on DIS
Two indices of DIS activity in the presence of ARV medications were examined with
simultaneous, chronic dosing of both the ARV of interest and DIS. The DIS intermediary
metabolite, DIS carbamate, is formed following metabolism via the CYP 450 enzyme
system and, therefore, is one measure of the effect of ARV medications, which have the
potential to alter CYP 450 function, on DIS efficacy. Table 3 shows a dose response for DIS
pharmacokinetics parameters as demonstrated by the DIS metabolite, DIS carbamate, for the
DIS 62.5 mg daily dose vs. the DIS 250 mg daily dose. A significant effect of ARV
administration on pharmacokinetics parameters for DIS 250 mg daily including Cmax, Cmin,
and AUC0–10and for DIS 62.5 mg daily Cmax and AUC0–10was observed. The differences
were related to significantly lower DIS carbamate Cmax, Cmin, and AUC0–10 with EFV
administration (Table 3, Figure 1). The second measure of DIS activity was examination of
ALDH activity. ALDH inhibition is the means by which alcohol metabolism is attenuated
resulting in a noxious reaction with alcohol consumption when clinical doses (DIS 250 mg
daily) are utilized in the treatment of alcohol use disorders. Figure 3 shows reductions in
ALDH activity when DIS 250 mg/d is administered alone (p=0.02) and represents a 44%
decrease in ALDH activity in this sample. ALDH activity is also significantly decreased
when RTV 200 mg/d is administered concurrently with DIS 250 mg/d (p= 0.009) and
represents a 36% decrease in ALDH activity. ATV co-administration with DIS 250 mg/d
resulted in a 16% reduction in ALDH activity (NS). EFV co-administration with DIS 250
daily resulted in the highest levels of ALDH inhibition at 52% (p=0.002).
Discussion
This study shows that DIS can be safely used with commonly prescribed ARV including
RTV, ATV, and EFV. DIS has no effect on the pharmacokinetics of any of these
medications; therefore ARV dose adjustments when using DIS for treatment of substance
use disorders in those receiving these ARV should not be necessary. Two of the ARV
studied had significant effects on DIS metabolism. EFV co-administration was associated
with significant decreases in DIS carbamate and a moderate increase in ALDH inhibition
relative to DIS alone administration. ATV administration with DIS 250 mg daily was
associated with a lack of DIS-associated inhibition of ALDH activity. This indicates that
DIS at standard clinical doses utilized in the treatment of alcohol use disorders is unlikely to
be effective; i.e.: a DIS-alcohol reaction may not occur in an individual receiving an ATV-
containing regimen for HIV infection and DIS for an alcohol disorder.
This study was undertaken because the hazardous use of alcohol as well as alcohol use
disorders are common in those with HIV infection (9–11), yet pharmacotherapies for alcohol
use disorders are infrequently used in the population. This might be largely due to the sparse
evidence currently available on the interactions of DIS and ARV. Informing clinicians of the
safety of DIS with concurrent use of ARV as well as identifying potential problems in the
use of this alcohol pharmacotherapy which has also shown promise in the treatment of
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cocaine dependence (4) may be helpful in increasing the clinical use of DIS in the HIV-
infected population.
Several studies have indicated inhibitory effects of DIS treatment on CYP450 enzymatic
activity (e.g. CYP3A4) which are variable (20, 31, 32). A number of ARV are substrates of
CYP3A4 including those in this study, EFV (22), ATV (33), and RTV (32). DIS was
administered at two doses: 62.5 mg/d and 250 mg/d because these doses have been shown to
diminish acute cocaine responses in humans (5). The finding that neither dose had a
significant effect on the pharmacokinetics of any of the ARV studied suggests that DIS in
clinically relevant doses can be safely used as it pertains to ARV efficacy in HIV-infected
people receiving ARV therapy. Of note, the RTV formulation administered in this study was
an alcohol-containing gelcap. No participants receiving RTV with DIS experienced
symptoms of an alcohol-DIS reaction.
The effect of the ARV on DIS metabolism and ALDH inhibition was consistent with study
hypotheses. EFV is known to induce CYP450 enzyme activity; specifically CYP3A4 (21).
DIS carbamate, an intermediate in DIS metabolism, is metabolized to S-methyl N,N-
diethylthiolcarbamate sulfoxide (DETC-MeSO) by CYP3A4, -2A6, and -2E1 (14) and
therefore, it was expected that levels of DIS carbamate would be lower in those receiving
EFV as compared to those receiving DIS alone. DETC-MeSO is the DIS metabolite
responsible for ALDH inhibition (14). The induction of CYP enzyme activity by EFV would
be expected to produce increased DETC-MeSO which would be manifest as a relative
increase in the inhibition of ALDH activity. This was observed in that ALDH activity
showed the greatest decrease in those receiving EFV and DIS concomitantly with a 52%
decline in ALDH activity observed (baseline 363.07 (40.46) mean (SE) vs. following EFV
600 mg/d and DIS 250 mg/d: 174.75 (23.18) (p = 0.002) (shown graphically in Figure 3). As
a comparison, baseline ALDH activity in those receiving only DIS 250/d was 416.46
(71.41), which declined to 233.89 (26.14) following DIS 250 mg/d administration (44%
decrease from baseline p = 0.020). ATV and RTV were expected to reduce the conversion of
the DIS carbamate to DETC-MeSO due to their inhibition of CYP3A4 (23, 34). Thus, it was
expected that co-administration of these ARV with DIS would be associated with
proportionately less inhibition of ALDH activity relative to disulfiram alone administration.
Among subjects receiving RTV 200 mg/d and DIS 250 mg/d, baseline ALDH activity
[593.17 (54.6)] significantly declined to 377.28 (42.57) (36% reduction) (p=0.009). A non-
significant (16%) decline in ALDH activity from 318.7 (38.91) to 266.36 (39.91) was
observed among subjects receiving ATV 400 mg/d with DIS 250 mg/d (shown graphically
in Figure 2). It is notable that there was significant variation in individual ALDH activity at
baseline; therefore the proportional change in ALDH activity was used as the comparator in
this study. Proportional changes in ALDH activity were consistent with the expected effect
of the ARV on CYP 450 activity.
One difference observed in subjects participating in the ATV and DIS study was an increase
in total bilirubin when ATV was administered alone or with DIS. ATV is known to inhibit
bilirubin glucuronidation by UDP glucuronosyltransferase 1A1 (UGT 1A1) with a resultant
increase in serum bilirubin levels that rapidly reverses on drug discontinuation (35). This
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hyperbilirubinemia occurs without concomitant increases in transaminases and is not
regarded as a sign of liver dysfunction (36).
One of the implications of the effect of ATV on glucuronidation would be in the potential
for inhibition of a contributing pathway for metabolism of some DIS metabolites
(diethyldithiocarbamate, for example). In humans, glucuronidation has been shown to be
responsible for elimination of 1.7% of a single 250 mg dose of DIS while 8.3% of DIS is
eliminated by glucuronidation with chronic dosing (37). The inhibition of glucuronidation
by co-administration of ATV might increase the amount of DIS metabolite that is subject to
CYP 450 metabolism. The inhibition of CYP 3A4 by ATV (34) could result in accumulation
of DIS metabolites and a concomitant decrease in the DIS metabolite responsible for
inhibition in ALDH (DETC-MeSO). We observed a decrease in ALDH inhibition by DIS
when administered with ATV, but we cannot say with certainty the mechanism by which
this occurred since we were unable to measure all of the metabolites formed in the DIS
metabolic pathway.
A question arising from these results is whether DIS at standard clinical doses used in the
treatment of alcohol use disorders (i.e.: 250 mg/d) would be effective as a deterrent to
alcohol use in those receiving antiretroviral therapies that contain either EFV, RTV, or
ATV. It is not possible to answer this question with precision because no studies have
correlated the proportion of reduction in ALDH activity with the occurrence or severity of a
DIS-alcohol reaction. However, in the current study there were two participants who
consumed alcohol within 3 days of discontinuation of DIS 250 mg/d (this occurred
following completion of study procedures). Both reported flushing, and one reported a
sensation of labored breathing while the second alcohol consumer stated that mild nausea
was the most prominent symptom. Each stated that they had started to experience these
symptoms after drinking less than one glass of wine. They were told to immediately
discontinue alcohol use and to come for medical evaluation if symptoms worsened. Both
reported discontinuation of symptoms within a few hours and neither required medical
intervention. ALDH inhibition relative to their baseline ALDH function was determined for
each of these individuals and found to be 31% for one subject and 68% for the second
participant. While inexact, it would appear that the proportion of ALDH inhibition that
occurs in an individual is related to the ability to mount a DIS-alcohol interaction with
alcohol consumption while taking DIS. It appears, then, from these results that EFV would
not be expected to interfere with DIS-mediated ALDH inhibition, nor were any adverse
events associated with the 8% additional ALDH inhibition observed relative to the sample
receiving DIS 250 mg/d alone. RTV administration, while associated with a lesser reduction
in ALDH inhibition over that observed with DIS alone administration is also not likely to
interfere with the occurrence of a DIS-alcohol reaction. ATV administration with DIS 250
mg/d was associated with only a 16% reduction in ALDH activity observed when these
medications were administered concomitantly. This may render DIS at standard clinical
doses as administered in this study ineffective. Human laboratory studies that include
alcohol administration following concomitant administration of clinically relevant doses of
the ARV and DIS would be able to conclusively answer the question of DIS efficacy for
alcohol dependence in those requiring ART that include these HIV therapeutics.
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DIS has also been studied as a treatment for cocaine dependence. The proposed mechanism
by which disulfiram alters cocaine responses has been postulated to be related to inhibition
of dopamine beta hydroxylase activity which occurs through the disulfiram metabolite,
diethyldithiocarbamate (DDTC) (38). Upon oral ingestion, DIS is rapidly reduced to its
corresponding thiol, diethyldithiocarbamate (DDTC) (39) and DDTC inactivates dopamine
beta hydroxylase by chelation. Because this is the first compound formed in the DIS
metabolic cycle; there is no expectation that the effect of ARV on CYP 450 enzyme function
would have an effect on this activity. If the hypothesized mechanism for DIS effect on
cocaine responses is correct, then DIS would still be expected to be effective for treatment
of cocaine use disorders in those receiving ART that contained any of the ARV studied.
There are limitations to this study. The number of ARV studied was limited and sample
sizes were relatively small. To address these limitations, ARV selected for study were those
expected to be likely to have interactions with DIS based on their known clinical
pharmacology, although there are a large number of ARV of potential interest in terms of
interactions with DIS. The study design would have benefitted from an assay to detect
DETC-MeSO and this was planned at the outset of the study. However, the development of
a reliable assay proved challenging leading to the use of DIS carbamate and ALDH activity
as surrogate markers of the effects of the ARV studied on DIS.
In summary, the results of drug interaction studies between three ARV that are frequently
used in the treatment of HIV infection and DIS are reported. No effect of DIS on ARV
pharmacokinetics at standard therapeutic doses of medications was observed, although EFV
lowered DIS carbamate plasma concentrations. EFV and RTV did not interfere with the
development of significant ALDH inhibition by DIS as was observed with ATV
administration, indicating that DIS at standard clinical doses may not be effective in
deterring alcohol use if given concomitantly with ATV.
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Effect of Antiretroviral Medications on S-Methyl-N-N-diethylthiocarbamate (DIS
Carbamate) at A. Disulfiram 62.5 mg daily or B. Disulfiram 250 mg daily
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Effect of Disulfiram in Combination with Antiretroviral Medications on ALDH Activity
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Age (yrs) 38.1 (4.2)# 43.4 (2.5) 44.9 (4.0) 33.8 (4.4)
Weight (kg) 75.1 (4.9) 79.7 (6.1) 76.6 (5.5) 87.4 (5.9)
Female 6 [60%] 3 [30%] 4 [40%] 3 [30%]
Race:
  African-American 2 [20%] 3 [30%] 2 [20%] 3 [30%]
  Caucasian 8 [80%] 7 [70%] 8 [80%] 3 [30%]
  Other 0 [0%] 0 [0%] 0 [0%] 4 [40%]
Nicotine Use (packs/day) 0.0 (0.0) 0.1 (0.1) 0.1 (0.1) 0.0 (0.0)
  AST (U/L)
  Normal Range: 10–41 U/L
    Baseline 25.1 (2.1) 28.9 (2.4) 27.3 (1.8) 24.1 (1.8)
    ARV Alone 25.1 (0.8) 32.9 (7.3) 21.7 (1.7)
    DIS 250 mg 27.0 (2.4) 22.9 (0.9) 35.0 (8.7) 29.1 (6.8)
  ALT (U/L)
  Normal Range: 7–35 U/L
    Baseline 23.3 (2.9) 25.4 (2.7) 23.9 (2.5) 21.9 (4.1)
    ARV Alone 20.4 (2.1) 23.6 (3.0) 19.9 (2.4)
    DIS 250 mg 24.4 (3.6) 20.2 (1.8) 37.2 (10.1) 26.8 (5.2)
  ALK Phosphate (U/L)
  Normal Range: 42–98 U/L
    Baseline 73.5 (6.2) 71.8 (4.3) 71.9 (4.3) 85.1 (5.3)
    ARV Alone 65.8 (4.5) 62.5 (6.3) 82.2 (5.3)
    DIS 250 mg 76.3 (7.1) 67.5 (4.1) 80.1 (5.0) 86.6 (5.2)
  Total Bilirubin (mg/dL)
  Normal Range: 0.1–1.2 mg/dL
    Baseline 0.6 (0.1) 0.7 (0.1) 0.7 (0.1) 0.6 (0.1)
    ARV Alone 0.5 (0.0) 0.4 (0.0) 2.3 (0.4)*
    DIS 250 mg 0.6 (0.1) 0.4 (0.0) 0.4 (0.0) 2.0 (0.5)*
  Total Protein (g/dL)
  Normal Range: 6.4–8.3 g/dL
    Baseline 7.4 (0.2) 7.1 (0.1) 7.2 (0.1) 7.4 (0.1)
    ARV Alone 6.6 (0.1) 6.8 (0.1) 6.9 (0.1)
    DIS 250 mg 7.1 (0.1) 6.6 (0.1) 7.0 (0.2) 7.1 (0.1)































  ECG QTc (ms)
    Baseline 420.4 (5.4) 409.0 (4.7) 415.1 (4.8) 404.5 (5.0)
    ARV Alone 410.6 (5.6) 415.3 (5.6) 384.9 (6.8)
    DIS 62.5 mg 421.8 (3.9) 409.6 (5.6) 407.0 (8.8) 383.8 (5.9)
    DIS 250 mg 420.8 (6.5) 403.7 (6.3) 403.1 (6.0) 380.4 (7.1)
#
Mean (SE), [ ] percent of sample affected
*
p ≤0.01
Other Race includes Hispanic, Native American, Pacific Islander and Multi-Racial individuals
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Table2
Effect of Disulfiram on Antiretroviral Medication Pharmacokinetics
A. Ritonavir (RTV) pharmacokinetics during disulfiram co-administration
Parameter RTV RTV/DIS62.5 RTV/DIS250 p
AUCtau(h*ng/ml) 9369 (978) 10899 (1069) 10960 (1343) 0.715
Clss/F (ml/h) 22977 (1995) 19992 (2020) 20501 (2161) 0.714
Cmax (ng/ml) 1399 (151) 1669 (243) 1758 (248) 0.568
Tmax (h) 5.0 (1.5–6.0) 4.0 (1.0–6.0) 4.0 (2.0–6.0) 0.332
T1/2 (h) 3.2 (0.5) 2.9 (0.2) 3.0 (0.3) 0.798
B. Atazanavir (ATV) pharmacokinetics during disulfiram co-administration
Parameter ATV ATV/DIS62.5 ATV/DIS250 p
AUCtau(h*ng/ml) 21895 (3407) 25411 (3011) 23127 (3030) 0.698
Clss/F (ml/h) 23515 (4112) 18586 (2867) 21250 (3538) 0.698
Cmax (ng/ml) 2823 (414) 3602 (409) 3571 (467) 0.426
Tmax (h) 4.0 (1.5–6.0) 2.0 (1.5–4.0) 2.0 (1.5–4.0) 0.342
T1/2 (h) 8.3 (1.1) 7.8 (0.8) 7.4(0.7) 1.939
C. favirenz (EFV) pharmacokinetics during disulfiram co–administration
Parameter EFV EFV/DIS62.5 EFV/DIS250 p
AUCtau(h*µg/ml) 166.5 (45.4) 166.3 (57.6) 234.9 (118.7) 0.882
Clss/F (l/h) 10.4 (1.0) 11.2 (1.1) 11.3 (1.0) 0.517
Cmax (µg/ml) 4.6 (0.5) 4.8 (0.9) 4.4 (0.5) 0.983
Tmax (h) 4.0 (1.0–12.0) 4.0 (2.0–8.0) 4.0 (2.0–8.0) 0.862
T1/2 (h) 29.3 (4.7) 29.1 (4.7) 29.3 (4.9) 0.847
*
Note: Values are the mean (standard error of the mean) for 10 subjects who participated in the study in each group, except that the discontinuous
variable, Tmax, is given as median (range).
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Table 3
Comparative pharmacokinetics for S-Methyl-N-N-diethylthiocarbamate (DIS carbamate) following disulfiram











DIS62.5 3.8±1.0 8.7±1.9 0.96±0.2 48.4±9.5
EFV+DIS62.5 2.5±0.6 2.2±0.7* 0.28±0.1 16.9±4.2*
RTV+DIS62.5 2.6±0.6 5.9±0.9 0.56±0.30 49.7±9.9
ATV+DIS62.5 3.1±0.6 8.0±1.3 0.90±0.3 49.6±8.5
p value 0.558 0.004 0.271 0.020
DIS250 3.1±0.6 35.6±5.2 7.6±1.1 230.4±29.4
EFV+DIS250 2.4±0.5 11.7±2.9* 1.1±0.4* 103.1±20.3*
RTV+DIS250 2.0±0.4 39.5±5.4 3.9±0.8 328.0±41.8
ATV+DIS250 2.9±0.5 32.1±4.6 5.3±1.4 200.3±27.9
p value 0.483 0.001 <0.0001 0.001
Note: Values are the mean (standard error of the mean) for 10 subjects who participated in the study in each group.
*
Significantly different from the control
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